E3 PreliminaryPreliminaryPEM ?MechanisticPeer-reviewedMachine draft
Effect of Kuibitang on lipopolysaccharide-induced cytokine production in peripheral blood mononuclear cells of chronic fatigue syndrome patients.
Shin, Hye-Young, An, Nyeon-Hyoung, Cha, Yun-Jin et al. · Journal of ethnopharmacology · 2004 · DOI
Quick Summary
This study tested whether Kuibitang (KBT), a traditional herbal treatment used in South Korea, could affect immune system chemicals in people with ME/CFS. Researchers added KBT to blood cells from CFS patients and healthy people, then stimulated those cells to see how they responded. They found that KBT reduced some inflammatory chemicals but increased others, suggesting it might help balance the abnormal immune responses seen in CFS.
Why It Matters
ME/CFS is characterized by dysregulated immune function and abnormal cytokine production, and current treatment options are limited. This study provides mechanistic evidence that an ethnobotanical compound may help normalize immune signaling in CFS patients, which could inform development of new therapeutic approaches and validate the clinical use of traditional remedies.
Observed Findings
- Kuibitang at 1 mg/ml reduced LPS-induced TNF-α production in CFS patient PBMCs
- Kuibitang at 1 mg/ml reduced LPS-induced IL-10 production in CFS patient PBMCs
- Kuibitang at 1 mg/ml reduced LPS-induced TGF-β1 production in CFS patient PBMCs
- Kuibitang at 0.01 mg/ml increased LPS-induced IFN-γ production in CFS patient PBMCs
Inferred Conclusions
- Kuibitang has immunomodulatory properties that may help regulate aberrant cytokine responses in CFS patients
- The herbal preparation may shift immune balance toward patterns that differ from those observed in untreated CFS
- Dose-dependent effects suggest there may be optimal concentrations for therapeutic use
Remaining Questions
- What is the effective dose range of Kuibitang in living CFS patients, and do in vitro findings translate to clinical benefit?
- Which bioactive compounds in Kuibitang are responsible for these immunomodulatory effects?
- Do these cytokine changes correspond to symptom improvement or functional recovery in CFS patients?
- How does long-term treatment with Kuibitang affect immune function compared to short-term ex vivo exposure?
What This Study Does Not Prove
This study does not demonstrate that Kuibitang actually treats or cures ME/CFS in living patients—it only shows laboratory effects on isolated blood cells. The findings do not establish which concentration would be effective in people, whether these immune changes would translate to clinical improvement, or whether the effects would persist over time with actual treatment.
Tags
Symptom:Fatigue
Biomarker:CytokinesBlood Biomarker
Method Flag:Weak Case DefinitionSmall SampleExploratory Only
Metadata
- DOI
- 10.1016/j.jep.2003.10.006
- PMID
- 15013189
- Review status
- Machine draft
- Evidence level
- Early hypothesis, preprint, editorial, or weak support
- Last updated
- 8 April 2026